A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

Clinical and Translational Oncology

Volumn 17, Issue 4, 2015, Pages 330-338

  Hernandez Prieto S ^a   Romera, A ^a   Ferrer, M ^a   Subiza, J L ^a   Lopez Asenjo J A ^a   Jarabo, J R ^a   Gomez A M ^a   Molina, Elena M ^a   Puente, J ^a   Gonzalez Larriba J L ^a   Hernando, F ^a   Perez Villamil B ^a   Diaz Rubio E ^a   Sanz Ortega, J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Early stages; Gene expression; Immune response; Molecular classification; Non small cell lung cancer; Relapse free survival

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD57 ANTIGEN; CD79 ANTIGEN; CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHRONIC INFLAMMATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; KERATINIZATION; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NON SMALL CELL LUNG CANCER; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

AGED; B-LYMPHOCYTES; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING;

EID: 84925506220     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1235-1     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
2. Vallières E, Shepherd FA, Crowley J, Van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung cancer staging project: proposals regarding the relevance of TNM in the pathologic staging of NSCLC in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(9):1049–59.
3. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A et al. eds.: AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 253–704.
4. Agulló-Ortuño MT, López-Ríos F, Paz-Ares L. Lung cancer genomic signatures. J Thorac Oncol. 2010;5(10):1673–91.
5. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006;24:1679–88.
6. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol. 2008;26(6):877–83.
7. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected NSCLC. J Clin Oncol. 2010;28(29):4417–24.
8. Lu Y, Lemon W, Liu P-Y, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I NSCLC. PLoS Med. 2006;3(12):e467.
9. Roepman P, Jassem J, Smit EF, Muley T, Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic profile for early-stage NSCLC. Clin Cancer Res. 2009;15(1):284–90.
10. Zhu CQ, Pintilie M, John T, Strumpf D, Shepherd FA, Der SD, et al. Understanding prognostic gene expression signatures in lung cancer. Clin Lung Cancer. 2009;10(5):331–40.
11. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage NSCLC. J Clin Oncol. 2007;25:5562–9.
12. Neumann J, Feuerhake F, Kayser G, Wiech T, Aumann K, Passlick B, et al. Gene expression profiles of lung adenocarcinoma linked to histopathological grading and survival but not to EGF-R status: a microarray study. BMC Cancer. 2010;10:77.
13. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegmanet P et al. Gene expression-based classification of NSCLC and survival prediction. PloS One 2010; 5(4): e10312.
14. Bryant CM, Albertus DL, Kim S, Chen G, Brambilla C, Guedj M et al. Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One 2010;22; 5(7):e11712.
15. Wan YW, Sabbagh E, Raese R, Qian Y, Luo D, Denvir J et al. Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One 2010;17;5(8):e12222.
16. Zhu CQ, Strumpf D, Li CY, Li Q, Liu N, Der S, et al. Prognostic gene expression signature for SCC of lung. Clin Cancer Res. 2010;16:5038.
17. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. A practical molecular assay to predict survival in resected non-squamous, NSCLC: development and international validation studies. Lancet. 2012;379:823–32.
18. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez Campos G, Calles A, Sanz-Ortega J, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer. 2012;12:260.
19. Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, et al. Adjustment of systematic microarray data bases. Bioinformatics. 2003;20(1):105–14.
20. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA. 2002;99(10):6567–72.
21. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131–135.
22. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst. 2010;102:464–74.
23. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst. 2007;99(2):147–57.
24. Perez-Andres M, Paiva B, Nieto WG, Caraux J, Schmitz CA, Almeida J, et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010;78B(Suppl. 1):S47–60.
25. Tangye SG, Good KL. Human IgM+ CD27+ B cells: memory B cells or “memory” B cells? J Immunol. 2007;179(1):13–9.
26. White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev. 2003;17(15):1813–6.
27. Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 2011;25(7):1182–8.
28. Trinidad EM, Ballesteros M, Zuloaga J, Zapata A, Alonso-Colmenar LM. An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. Blood. 2009;114(24):5081–90.
29. Shapiro MJ, Nguyen CT, Aghajanian H, Zhang W, Shapiro VS. Negative regulation of TCR signaling by linker for activation of X cells via phosphotyrosine-dependent and -independent mechanisms. J Immunology. 2008;181:7055–61.
30. Zikos AD, Donnenberg RJ, Landreneau JD, Luketich JD, Donnenberg VS. Lung T-cell subset composition at the time of surgical resection is a prognostic indicator in NSCLC. Cancer Immunol Immunother. 2011;60:819–27.
31. Hagn M, Sontheimer K, Dahlke K, Brueggemann S, Kaltenmeier C, Beyer T, et al. Human B cells differentiate into granzyme B-secreting cytotoxic B lymphocytes upon incomplete T-cell help. Immunol Cell Biol. 2012;90(4):457–67.
32. Chen H-Y, Yu S-L, Chen C-H, Chang GC, Chen CY, Yuan A, et al. A five gene signature and clinical outcome in NSCLC. N Engl J Med. 2007;356:11–20.
33. Mahabeleshwar GH, Das R, Kundu GC. Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of EGFR/extracellular signal regulated kinase pathways. J BiolChem. 2004;279:9733–42.
34. Majolini MB, D’Elios MM, Galieni P, Boncristiano F, Lauria G, Del Prete JL, et al. Expression of the T-cell-specific tyrosine kinase lck in normal B-1 cells and in chronic lymphocytic leukemia B cells. Blood. 1998;91:3390–6.
35. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871–80.
36. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP, et al. Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res. 2001;61(21):7889–99.
37. Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol. 2005;175(4):2278–85.
38. Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1–4.
39. Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, et al. Prognostic immune markers in NSCLC. Clin Cancer Res. 2011;17(16):5247–56.
40. Hernando F, Sanz J, Jarabo JR, et al. A new genetic signature defining two prognostic groups among patients with completely resected early non-small cell lung cancer. J Thor Oncol. 2012;7(6):S59.
41. Sanz J, Hernandez S, Hernando F, Larriba JLG, Puente J, Ferrer M, et al. An intratumoral B-cell immune response determines favorable prognosis for early stage lung cancer and can be assessed by different immunoscores. Modern Pathol. 2013;26:466A.